88 results on '"Prins, Robert M."'
Search Results
2. Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma
3. Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors
4. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1
5. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma
6. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI
7. Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry
8. Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas
9. Epithelial membrane protein-2 (EMP2) promotes angiogenesis in glioblastoma multiforme
10. Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors.
11. Amine‐weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumors.
12. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
13. Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities
14. Endogenous Vaults and Bioengineered Vault Nanoparticles for Treatment of Glioblastomas: Implications for Future Targeted Therapies
15. Spatial immune profiling of glioblastoma identifies an inflammatory, perivascular phenotype associated with longer survival.
16. The AMPK Agonist AICAR Inhibits the Growth of EGFRvlll-Expressing Glioblastomas by Inhibiting Lipogenesis
17. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy
18. Immunosensitization with a Bcl-2 small molecule inhibitor
19. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
20. Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain
21. Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.
22. Thymic Function and Output of Recent Thymic Emigrant T Cells During Intracranial Glioma Progression
23. Irradiated tumor cell vaccine for treatment of an established glioma. I. Successful treatment with combined radiotherapy and cellular vaccination
24. Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression
25. Cytotoxic T cells infiltrating a glioma express an aberrant phenotype that is associated with decreased function and apoptosis
26. Identification of Retinol Binding Protein 1 Promoter Hypermethylation in Isocitrate Dehydrogenase 1 and 2 Mutant Gliomas
27. Is there a role for neoadjuvant anti-PD-1 therapies in glioma?
28. Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications
29. Contrasting effects of interleukin-2 secretion by rat glioma cells contingent upon anatomical location: accelerated tumorigenesis in the central nervous system and complete rejection in the periphery
30. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas Ligand pathway
31. Cellular and vaccine therapeutic approaches for gliomas
32. Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy.
33. Commentary on "Dysfunctional dendritic cells limit antigen-specific T cell response in glioma".
34. Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI.
35. Evidence for Innate and Adaptive Immune Responses in a Cohort of Intractable Pediatric Epilepsy Surgery Patients.
36. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.
37. Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma.
38. pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI.
39. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
40. 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling.
41. Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients.
42. Cellular and vaccine therapeutic approaches for gliomas.
43. EGFR Signaling Through an Akt-SREBP-1-Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy.
44. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.
45. Immunotherapy for patients with malignant glioma: from theoretical principles to clinical applications.
46. Central Nervous System Tumor Immunity Generated by a Recombinant Listeria monocytogenes Vaccine Targeting Tyrosinase Related Protein-2 and Real-Time Imaging of Intracranial Tumor Burden.
47. Tumor immunology, immunomics and targeted immunotherapy for central nervous system malignancies.
48. 214 Noninvasive Monitoring of Immunotherapeutic Responses in Glioblastoma Using Novel Imaging Techniques.
49. 198 An Antigen Vault Nanoparticle Vaccine Can Effectively Stimulate Dendritic Cells and Activate a Specific T cell Immune Response.
50. Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.